Kennedy Capital Management LLC Has $2.47 Million Stake in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Kennedy Capital Management LLC boosted its stake in shares of Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) by 36.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 809,375 shares of the biopharmaceutical company's stock after acquiring an additional 216,329 shares during the quarter. Kennedy Capital Management LLC owned 1.65% of Puma Biotechnology worth $2,469,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Gateway Wealth Partners LLC acquired a new stake in shares of Puma Biotechnology in the 4th quarter valued at $31,000. C2C Wealth Management LLC acquired a new stake in Puma Biotechnology in the fourth quarter worth about $37,000. Franklin Resources Inc. bought a new stake in Puma Biotechnology during the 3rd quarter worth about $41,000. Virtu Financial LLC acquired a new position in Puma Biotechnology during the 3rd quarter valued at about $68,000. Finally, Wells Fargo & Company MN grew its position in shares of Puma Biotechnology by 36.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,929 shares of the biopharmaceutical company's stock worth $70,000 after buying an additional 6,126 shares during the period. 61.29% of the stock is owned by institutional investors.

Analysts Set New Price Targets

PBYI has been the topic of a number of recent research reports. StockNews.com raised shares of Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Puma Biotechnology in a research note on Friday, February 28th.

Puma Biotechnology Trading Down 0.7 %

Shares of PBYI stock traded down $0.02 on Friday, reaching $2.86. The company had a trading volume of 224,010 shares, compared to its average volume of 442,421. The stock has a market cap of $141.89 million, a PE ratio of 5.96 and a beta of 1.34. The company has a 50-day moving average of $3.10 and a 200-day moving average of $3.01. The company has a current ratio of 1.42, a quick ratio of 1.40 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 12 month low of $2.23 and a 12 month high of $5.34.

Puma Biotechnology (NASDAQ:PBYI - Get Free Report) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share for the quarter, topping the consensus estimate of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million for the quarter, compared to analyst estimates of $52.50 million. On average, equities analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.